Kymab

Kymab

Kymab is discovering and developing fully human ...

Other | United Kingdom of Great Britain and | Access to Information |

 

Overview

Founded in 2009, Kymab raised $30m of equity financing in 2010 from The Wellcome Trust Investment Division to enable the development of the Kymouse™ platform and create a portfolio of therapeutic assets. In 2014, The Bill and Melinda Gates Foundation together with The Welcome Trust invested a further $40 million in Kymab. This enables their mission to advance their pipeline of first-in-class therapeutics and embark on vaccine development in areas of high unmet medical need.



The company leveraged technology developed in the laboratory of Professor Allan Bradley from The Sanger Institute, a world leading genomics research centre.

Industry

Legal Structure

Operating Status

Employees

Other Operating

Funding and Financing Rounds


Team


Impact

Social Objectives:

Environmental Objectives:

Operational Impact:


Impact Reports & Metrics


Offices

Headquarters

Meditrina Babraham Research
Campus Cambridge, CB22 3AT
United Kingdom of Great Britai



Explore

Revision History


Quick Search



  • Global  
  • Africa  
  • Americas  
  • Asia  
  • Europe  
  • Oceania  


Incoming

Tags

COPYRIGHT 2017 IMPACTSPACE. ALL RIGHTS RESERVED.